[¹¹C]MeRo25, a Unique Chemotype PET Radioligand, Shows Robust Brain Uptake But Insufficient Selectivity for GluN2B Imaging
Authors:
- Lisheng CaiLCLisheng Cai
- Jeih-San LiowJLJeih-San Liow
- Xuefeng YanXYXuefeng Yan
- Cheryl L. MorseCMCheryl L. Morse
- Alyssa J. WangAWAlyssa J. Wang
- Leah N. MillardLMLeah N. Millard
- Baku AcharyaBABaku Acharya
- Yonglan LiuYLYonglan Liu
- Sean W. CostnerSCSean W. Costner
- Sami S. ZoghbiSZSami S. Zoghbi
- Robert B. InnisRIRobert B. Innis
- Victor W. PikeVPVictor W. Pike
Preprint
- 30 September 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: GluN2B-subunits of N-methyl-D-aspartate (NMDA) receptors are therapeutic targets for neuropsychiatric disorders, but an effective positron emission tomography (PET) radioligand for human GluN2B brain imaging is still needed. We developed [11C]MeRo25, a 11C-methylated derivative of the GluN2B-preferring ligand Ro 25-6981 and evaluated its suitability as a GluN2B PET radioligand. Methods: MeRo25 was synthe-sized by methylation of Ro 25-6981, and affinities for GluN2B and σ1 receptors were de-termined in vitro. [11C]MeRo25 was prepared using [11C]methyl iodide. PET studies were performed in rats and monkeys at baseline and after challenge with GluN2B or σ1 recep-tor-directed ligands. In monkeys, regional total distribution volume (VT) was estimated by kinetic modeling. Results: MeRo25 showed low nanomolar affinity for GluN2B and σ1 re-ceptors. [11C]MeRo25 was obtained in 20–30% radiochemical yield, > 99% purity, and high molar activity. [11C]MeRo25 showed rapid and high brain uptake in rats and monkeys. Pretreatment with either GluN2B or σ1 receptor-directed ligands in monkey markedly re-duced brain radioactivity and regional VT, demonstrating contributions from both receptor populations. Conclusions: Despite favorable brain uptake and high GluN2B affinity, [11C]MeRo25 exhibits substantial σ1 receptor binding, producing a mixed GluN2B/σ1 re-ceptor PET signal that precludes its use as a selective GluN2B radioligand. These findings emphasize the importance of in vivo pharmacological validation and reveal limitations of the Ro 25-6981 scaffold for selective GluN2B PET radioligand development. This study also cautions against the use of Ro 25-6981 as a pharmacological tool where binding to s1 receptors may be of concern, for example as a challenge agent in PET studies.Keywords
All Related Versions
- Version 1, 2026-09-30, Preprints
- Published version: Pharmaceuticals, 19 (11), 1713.
This publication has 33 references indexed in Scilit:
- Recent Progress in NMDA Glutamate Receptor Imaging2025
- In vivo evaluation of a novel 18F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brainEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate ReceptorsJournal of Medicinal Chemistry, 2018
- On Quantitative Relationships Between Drug-Like Compound Lipophilicity and Plasma Free Fraction in Monkey and HumanJournal of Pharmaceutical Sciences, 2012
- Ro 25–6981, a Highly Potent and Selective Blocker of N-Methyl-d-aspartate Receptors Containing the NR2B Subunit. Characterization in VitroThe Journal of Pharmacology and Experimental Therapeutics, 1997
- Immunoblot Analyses on the Differential Distribution of NR2A and NR2B Subunits in the Adult Rat BrainMolecules and Cells, 1997
- mRNA distribution in adult human brain of GRIN2B, a N-methyl-d-aspartate (NMDA) receptor subunitNeuroscience Letters, 1997
- Evaluation of Ultrafiltration for the Free‐Fraction Determination of Single Photon Emission Computed Tomography (SPECT) Radiotracers: β‐CIT, IBF, and IomazenilJournal of Pharmaceutical Sciences, 1994
- Developmental and regional expression in the rat brain and functional properties of four NMDA receptorsNeuron, 1994
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973